Imvax raises $112M to advance brain cancer cell therapy

Imvax has raised $112 million to take its autologous tumor cell vaccine into a phase 2 glioblastoma multiforme trial. The series C follows phase 1b data on the brain cancer treatment that persuaded existing investors including HP WILD Holding and Ziff Capital Partners to commit more cash.